TB-500 (Ac-LKKTETQ): Published Research, Chemical Identity and Batch Documentation
TB-500 is the N-acetylated seven-amino-acid peptide Ac-LKKTETQ (C38H68N10O14, 889.0 g/mol), matching residues 17–23, the actin-binding site of thymosin β4. It is a different molecule from full-length thymosin β4. Most published work studied the full protein; direct TB-500 studies are few and use rats, horses and in-vitro systems.

Batch documentation
Two documents stand behind each batch we list: the manufacturer COA and an independent ACS Peptide Testing Labs report, measured against a 98%+ purity floor. Below is the ACS result for the TB-500 batch.
| Batch tested | Ve2026-TB5-001 |
|---|---|
| Laboratory | ACS Peptide Testing Labs |
| Accession number | AAHV640 |
| Purity (LCMS-UV) | 99.73% |
| Mass identification | TB-500 |
| Reported | July 28, 2026 |
The result describes only the tested sample. View the COA and ACS report on the TB-500 product page.
What is TB-500? Chemical identity
| Sequence | Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ) [3] |
|---|---|
| CAS number | 885340-08-9 [PubChem] |
| Molecular formula | C38H68N10O14 [PubChem] |
| Molecular weight | 889.0 g/mol (computed) [PubChem] |
| PubChem CID | 62707662 [PubChem] |
| Not the same as | Full-length thymosin β4, a 4.9 kDa polypeptide [7] |
Identity values from PubChem CID 62707662. Acetate or other salt forms weigh more than the free peptide, so the batch COA takes precedence.
What have published studies on TB-500 examined?
Which molecule is in each row? The Model type tag says whether a row tested TB-500 itself or, as labeled, thymosin β4 or LKKTETQ. All rows are animal or in-vitro work, quoted as published for literature reference only. None is guidance, a recommendation or a protocol for any use.
| Model type | Model | Concentration or dose (as reported) | Route | Duration | Outcome (as reported) | Source |
|---|---|---|---|---|---|---|
| Animal (TB-500) | Rat, Achilles tendon transection and repair (n = 32) | 60 µg/kg/day TB-500; 10 µg/kg/day BPC-157; or both (as reported) | Intraperitoneal | 4 weeks | Higher maximum load to failure with TB-500 vs controls (p < 0.05) and lower Bonar/Movin scores; combination added no benefit; authors describe the study as exploratory | Biçer O 2026 [1] PMID 42542926 · DOI |
| In vitro + animal (TB-500) | Human serum and enzyme systems in vitro; rat urine; fibroblast assay | Not stated in abstract | Not stated in abstract | Rat urine sampled up to 72 h | Ac-LK was the main metabolite (0–6 h); Ac-LKK detected up to 72 h; no cytotoxicity; only the metabolite Ac-LKKTE showed wound-healing activity in the fibroblast assay | Rahaman KA 2024 [2] PMID 38382158 · DOI |
| Animal (TB-500, analytical) | Horses, doping-control detection | Single dose of a TB-500 preparation containing 10 mg N-acetylated LKKTETQ (as reported) | Not stated in abstract | Post-administration sampling | Detection method confirmed TB-500 and metabolites; limits 0.02 ng/mL (plasma) and 0.01 ng/mL (urine) | Ho EN 2012 [3] PMID 23084823 · DOI |
| Animal (thymosin β4 and LKKTETQ, not TB-500) | db/db diabetic mice; 26-month-old mice; rats; full-thickness dermal wounds | Not stated in abstract | Topical (PBS or hydrogel) | Not stated in abstract | Increased wound contracture and collagen deposition; non-acetylated LKKTETQ promoted repair in aged mice comparably to thymosin β4 | Philp D 2003 [4] PMID 12581423 · DOI |
| Animal + in vitro (thymosin β4, not TB-500) | Rat full-thickness wound; keratinocyte migration assay | As little as 10 pg in the migration assay; in-vivo amount not stated in abstract | Topical or intraperitoneal | 4 and 7 days | Re-epithelialization up 42% at day 4 and up to 61% at day 7 vs saline; keratinocyte migration up 2–3-fold | Malinda KM 1999 [5] PMID 10469335 · DOI |
| Animal + in vitro (thymosin β4, not TB-500) | Mouse coronary artery ligation; embryonic and postnatal cardiomyocytes | Not stated in abstract | Not stated in abstract | Not stated in abstract | Formed a complex with PINCH and integrin-linked kinase, activating Akt; improved early myocyte survival and cardiac function in mice | Bock-Marquette I 2004 [6] PMID 15565145 · DOI |
| In vitro (thymosin β4, not TB-500) | Human umbilical vein endothelial cells (cell culture); subcutaneous Matrigel | Not stated in abstract | Culture medium; Matrigel implant | Not stated in abstract | Endothelial migration up 4–6-fold in Boyden chambers; increased matrix metalloproteinase production | Malinda KM 1997 [7] PMID 9194528 · DOI |
Anecdotal or calculation only. Not dosing guidance or medical advice. For laboratory research use only.
Abstract-level data only: each parameter comes from the study’s PubMed record, and "Not stated in abstract" marks values that exist only in the full text and were not copied across.
What mechanisms have been reported for TB-500?
Statements here are scoped to their source: some concern the TB-500 heptapeptide, others the parent protein or related fragments, and all come from animal or in-vitro work.
- The sequence LKKTETQ (residues 17–23) is the actin-binding active site of thymosin β4, and TB-500 is this sequence with an acetylated N-terminus. [3]
- In aged mice, the non-acetylated synthetic heptapeptide LKKTETQ promoted dermal wound repair comparably to full-length thymosin β4. [4]
- Full-length thymosin β4 is a G-actin-sequestering peptide; in mouse heart studies it formed a complex with PINCH and integrin-linked kinase and activated Akt. [6]
- In rat and in-vitro metabolism studies, TB-500 was broken down mainly to Ac-LK, and only the metabolite Ac-LKKTE showed wound-healing activity in a fibroblast assay. [2]
TB-500 storage: what the supplier says
Unconfirmed supplier guidance: for the long term, keep TB-500 desiccated at −20 °C; for the short term, 2–8 °C. Keep it out of light, and warm the sealed vial to room temperature before opening to limit condensation.
We have not cited a TB-500 stability study, and the shelf life of reconstituted material is not established on this page. Rely on procedures your own laboratory has validated.
Why researchers source TB-500 from Vial & Error
- A published ACS Peptide Testing Labs report is on file.
- The 98%+ purity floor is evidenced by both the manufacturer COA and the third-party ACS result.
- The study table separates TB-500 from full-length thymosin β4 row by row, with a PMID or DOI behind each source.
Get TB-500 with its batch paperwork
Open the TB-500 product page to see its COA section and to order.
Open the TB-500 product page Check out with TB-500 in the cart
Comparing compounds first? See the BPC-157 study table or the GHK-Cu batch report.
Frequently asked questions
Is TB-500 the same as thymosin β4?
No. TB-500 is the acetylated seven-amino-acid fragment Ac-LKKTETQ. Thymosin β4 is the full-length protein, a 4.9 kDa polypeptide. Results for the full protein do not automatically apply to TB-500, which is why our study table labels each row.
What is the molecular weight of TB-500?
PubChem lists C38H68N10O14 and a computed molecular weight of 889.0 g/mol (CID 62707662, CAS 885340-08-9). Use the molecular weight on your batch COA if your material is a salt form.
Which studies tested TB-500 itself?
In our table, three rows tested TB-500 directly: a rat Achilles tendon study, an in-vitro and rat metabolism study, and an equine doping-control method. The other rows studied full-length thymosin β4 or non-acetylated LKKTETQ.
Which TB-500 batch was tested by ACS Peptide Testing Labs?
The current ACS Peptide Testing Labs report lists purity by LCMS-UV and mass identification for the sample tested. The result describes only the tested sample.
How should lyophilized TB-500 be stored?
The supplier’s guidance lists −20 °C desiccated for the long term and 2–8 °C for the short term, away from light. Manufacturer stability data have not yet confirmed it.
Do the TB-500 table figures guide dosing?
No. The figures describe what investigators used in their animal and in-vitro work, including an equine doping-control method, and nothing in the table is guidance for any use. TB-500 from Vial & Error is
References
- Biçer O, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026. PMID 42542926 · doi:10.52312/jdrs.2026.2951
- Rahaman KA, et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. J Chromatogr B Analyt Technol Biomed Life Sci. 2024. PMID 38382158 · doi:10.1016/j.jchromb.2024.124033
- Ho EN, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012. PMID 23084823 · doi:10.1016/j.chroma.2012.09.043
- Philp D, et al. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen. 2003. PMID 12581423 · doi:10.1046/j.1524-475x.2003.11105.x
- Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999. PMID 10469335 · doi:10.1046/j.1523-1747.1999.00708.x
- Bock-Marquette I, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004. PMID 15565145 · doi:10.1038/nature03000
- Malinda KM, et al. Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB J. 1997. PMID 9194528 · doi:10.1096/fasebj.11.6.9194528
[PubChem] National Center for Biotechnology Information. PubChem Compound Summary, CID 62707662.